Formulation Development
Nexcella Enters US GMP Manufacturing Agreement to Expand Ongoing Phase 1b/2 Clinical Trial
Nexcella, Inc. recently announced it has entered into a manufacturing agreement with a well-known United States Good Manufacturing Practice (GMP) cell therapy manufacturer that will…
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer
BioXcel Therapeutics, Inc. recently announced full data from its Phase 2a trial of BXCL701, the company’s investigational, oral innate immune activator, in combination with….
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
Purple Biotech Ltd. recently announced the first patient has been dosed in the randomized part of the open label Phase 2 clinical trial evaluating CM24…
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
Vaxart, Inc. recently announced it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus candidate. The dose-ranging…
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase 1/2 Clinical Trial of Regenerative Cell Therapy in Patients With Dominant Hemisphere Drug-Resistant Focal Epilepsy
Neurona Therapeutics recently announced the US FDA has cleared an amendment to Neurona’s ongoing Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial…
Catalent Appoints New Senior VP, General Counsel, Chief Compliance Officer & Secretary
[caption id="attachment_137301" align="alignleft" width="146"] Joseph A. Ferraro[/caption] Catalent, Inc. recently announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance…
Lonza to Expand Early Development Services Offering Into North America
Lonza recently announced it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, MA. The 17,000-sq-ft facility…
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial for Treatment of Moderate-to- Severe Vasomotor Symptoms Associated With Menopause
Acer Therapeutics Inc. recently announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R)…
Sermonix Pharmaceuticals & Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative recently announced Sermonix’s investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated in a new study arm…
Quotient Sciences Expands Formulation Development Capabilities to Further Accelerate Drug Development Timelines
Company increases laboratory capacity to meet customer demand for fully integrated drug development capabilities….
MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Pantherna & Evaxion Announce Promising Preclinical mRNA Vaccine Data
Evaxion Biotech A/S and Pantherna Therapeutics GmbH recently announced preclinical proof of concept for the combination of the two companies’ key….
EuMentis Therapeutics Inc. Receives $3-Million Award from US DoD to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
EuMentis Therapeutics Inc. recently announced it has received an award from the United States Department of Defense (DoD) to develop a novel small molecule therapeutic…
Bayer Announces First Patients Enrolled in Global Phase 3 Studies for Investigational Oral FXIa Inhibitor Asundexian
Bayer recently announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of…
Nectin Therapeutics to Collaborate With Merck on Clinical Trial of Anti-PVR Antibody in Combination with KEYTRUDA in Patients With Locally Advanced & Metastatic Solid Tumors
Nectin Therapeutics Ltd. recently announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Nectin will evaluate the safety, tolerability, and antitumor activity of its novel….
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101,…
Endogena Therapeutics Receives Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
Endogena Therapeutics Inc. recently announced the US FDA has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track…
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Immutep Limited recently announced the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating…
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
BD (Becton, Dickinson and Company) recently announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample…
